XML 151 R78.htm IDEA: XBRL DOCUMENT
v3.22.4

Segmentation of key figures (Details 8) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 50,545 | $ 51,626 | $ 48,659
Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 6.00% |
Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 41,296 | $ 41,995 | 39,013
Innovative Medicines | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 8.00% |
Operating segments [member] | Innovative Medicines |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 8.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 31,396 | $ 29,754 | 25,319
Net sales, change in % | 6.00% | 18.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 4,756 | $ 3,560 | 2,497
Net sales, change in % | 34.00% | 43.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 4,644 | $ 3,548 | 2,497
Net sales, change in % | 31.00% | 42.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Leqvio [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 112 | $ 12 |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 7,287 | $ 7,205 | 6,119
Net sales, change in % | 1.00% | 18.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 4,788 | $ 4,718 | 3,995
Net sales, change in % | 1.00% | 18.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,365 | $ 1,428 | 1,251
Net sales, change in % | (4.00%) | 14.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,133 | $ 1,059 | 873
Net sales, change in % | 7.00% | 21.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1 |  |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 5,051 | $ 5,007 | 4,272
Net sales, change in % | 1.00% | 17.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 2,013 | $ 2,787 | 3,003
Net sales, change in % | (28.00%) | (7.00%) |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,370 | $ 1,351 | 920
Net sales, change in % | 1.00% | 47.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,092 | $ 372 | 15
Net sales, change in % | 194.00% |  |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Mayzent [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 357 | $ 281 | 170
Net sales, change in % | 27.00% | 65.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Aimovig [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 218 | $ 215 | 164
Net sales, change in % | 1.00% | 31.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1 | $ 1 |
Net sales, change in % | 0.00% |  |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 4,723 | $ 4,101 | 3,666
Net sales, change in % | 15.00% | 12.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,770 | $ 1,693 | 1,542
Net sales, change in % | 5.00% | 10.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,231 | $ 937 | 687
Net sales, change in % | 31.00% | 36.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 474 | $ 577 | 635
Net sales, change in % | (18.00%) | (9.00%) |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Lutathera [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 471 | $ 475 | 445
Net sales, change in % | (1.00%) | 7.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Piqray [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 373 | $ 329 | 320
Net sales, change in % | 13.00% | 3.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Pluvicto [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 271 |  | 2
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tabrecta [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 133 | $ 90 | 35
Net sales, change in % | 48.00% | 157.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 6,452 | $ 6,430 | 5,617
Net sales, change in % | 0.00% | 14.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 2,088 | $ 2,016 | 1,738
Net sales, change in % | 4.00% | 16.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,923 | $ 2,060 | 1,958
Net sales, change in % | (7.00%) | 5.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,561 | $ 1,595 | 1,339
Net sales, change in % | (2.00%) | 19.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 536 | $ 587 | 474
Net sales, change in % | (9.00%) | 24.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 194 | $ 164 | 105
Net sales, change in % | 18.00% | 56.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Scemblix [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 149 | $ 7 |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1 | $ 1 | 3
Net sales, change in % | 0.00% | (67.00%) |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 3,127 | $ 3,451 | 3,148
Net sales, change in % | (9.00%) | 10.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,874 | $ 2,160 | 1,933
Net sales, change in % | (13.00%) | 12.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Xiidra [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 487 | $ 468 | 376
Net sales, change in % | 4.00% | 24.00% |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 479 | $ 584 | 623
Net sales, change in % | (18.00%) | (6.00%) |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Beovu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 203 | $ 186 | 190
Net sales, change in % | 9.00% | (2.00%) |
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Other Respiratory [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 84 | $ 53 | 26
Net sales, change in % | 58.00% | 104.00% |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 9,900 | $ 12,241 | 13,694
Net sales, change in % | (19.00%) | (11.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,238 | $ 1,413 | 1,439
Net sales, change in % | (12.00%) | (2.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 859 | $ 1,092 | 1,199
Net sales, change in % | (21.00%) | (9.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 745 | $ 1,024 | 1,188
Net sales, change in % | (27.00%) | (14.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 743 | $ 901 | 980
Net sales, change in % | (18.00%) | (8.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 652 | $ 773 | 1,003
Net sales, change in % | (16.00%) | (23.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 512 | $ 938 | 1,083
Net sales, change in % | (45.00%) | (13.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 334 | $ 373 | 360
Net sales, change in % | (10.00%) | 4.00% |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 329 | $ 431 | 452
Net sales, change in % | (24.00%) | (5.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 323 | $ 563 | 653
Net sales, change in % | (43.00%) | (14.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 310 | $ 368 | 393
Net sales, change in % | (16.00%) | (6.00%) |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Contract manufacturing [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 214 | $ 108 |
Net sales, change in % | 98.00% |  |
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Other [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 3,641 | $ 4,257 | $ 4,944
Net sales, change in % | (14.00%) | (14.00%) |

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BrandsAxis=nvs_PromotedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_EntrestoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LeqvioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_CosentyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XolairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_IlarisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GilenyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZolgensmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KesimptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_MayzentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AimovigMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_SolidTumorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TafinlarMekinistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KisqaliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VotrientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LutatheraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PiqrayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PluvictoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TabrectaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_HematologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_PromactaRevoladeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_TasignaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_JakaviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_KymriahMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AdakveoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ScemblixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_OtherPromotedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_LucentisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_XiidraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_UltibroGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_BeovuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_OtherRespiratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_BrandsAxis=nvs_EstablishedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_CoreTherapeuticAreaOtherPromotedBrandsAndEstablishedBrandsAxis=nvs_EstablishedBrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_SandostatinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GalvusGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_GleevecGlivecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExforgeGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_DiovanGroupMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_AfinitorVotubiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_VoltarenCataflamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ZortressCerticanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ExjadeJadenuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_NeoralSandimmunEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=nvs_ContractManufacturingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |